Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial
The American Journal of Clinical Nutrition · 2024
DOI: 10.1016/j.ajcnut.2024.06.016 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Clinical Nutrition, 2024. Verfasst von Gilmar Reis und 21 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Cardresearch-Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil; Department of Medicine, Pontifícia Univ…. Hauptthemen laut MEDLINE: Spirulina, Hospitalization, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Towards Sustainability Foundation.
Abstract (Originalsprache)
BACKGROUND: Algae-derived nutraceuticals, such as spirulina, have been reported to have biological activities that may minimize clinical consequences to COVID-19 infections. OBJECTIVES: This study aimed to determine whether spirulina is an effective treatment for high-risk patients with early COVID-19 in an outpatient setting. METHODS: The TOGETHER trial is a placebo-controlled, randomized, platform trial conducted in Brazil. Eligible participants were symptomatic adults with a positive rapid test for SARS-CoV-2 older than 50 y or with a known risk factor for disease severity. Patients were randomly assigned to receive placebo or spirulina (1 g twice daily for 14 d). The primary end point was hospitalization defined as either retention in a COVID-19 emergency setting for >6 h or transfer to tertiary hospital owing to COVID-19 at 28 d. Secondary outcomes included time-to-hospitalization, mortality, and adverse drug reactions. We used a Bayesian framework to compare spirulina with placebo. RESULTS: We recruited 1126 participants, 569 randomly assigned to spirulina and 557 to placebo. The median age was 49.0 y, and 65.3% were female. The primary outcome occurred in 11.2% in the spirulina group and 8.1% in the placebo group (odds ratio [OR]: 1.24; 95% credible interval: 0.84, 1.86). There were no differences in emergency department visit (OR: 1.21; 95% credible interval: 0.81, 1.83), nor time to symptom relief (hazard ratio: 0.90; 95% credible interval: 0.79, 1.03). Spirulina also not demonstrate important treatment effects in the prespecified subgroups defined by age, sex, BMI, days since symptom onset, or vaccination status. CONCLUSIONS: Spirulina has no any clinical benefits as an outpatient therapy for COVID-19 compared with placebo with respect to reducing the retention in an emergency setting or COVID-19-related hospitalization. There are no differences between spirulina and placebo for other secondary outcomes. This trial was registered at clinicaltrials.gov as NCT04727424.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Division, Cardresearch-Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil; Department of Medicine, Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazi…
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
- Research Division, Cardresearch-Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil.
- Department of Public Health at UniFipMoc and Family Medicine Fellowship Program, City of Montes Claros, Minas Gerais, Brazil.
- Public Health, Mental and Family Medicine Department, Ouro Preto Federal University, Ouro Preto, Minas Gerais, Brazil.
- Public Health Fellowship Program, Governador Valadares Public Health Authority, Minas Gerais, Brazil.
Förderung
- Towards Sustainability Foundation
Zitieren
APA
Reis, G., Augusto Dos Santos Moreira Silva, E., Carla Medeiros Silva, D., Thabane, L., Santiago Ferreira, T., Vitor Quirino Dos Santos, C., Paula Figueiredo Guimaraes Almeida, A., Cançado Monteiro Savassi, L., Dias de Figueiredo Neto, A., Lanna França Reis, L., Helena de Souza Campos, V., Bitarães, C., Diniz Callegari, E., Izabel Campos Simplicio, M., Barra Ribeiro, L., Oliveira, R., Harari, O., Forrest, J. I., Lat, P. K., …, & Mills, E. J. (2024). Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2024.06.016
Vancouver
Reis G, Augusto Dos Santos Moreira Silva E, Carla Medeiros Silva D, Thabane L, Santiago Ferreira T, Vitor Quirino Dos Santos C, et al. Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial. The American Journal of Clinical Nutrition. 2024. doi:10.1016/j.ajcnut.2024.06.016
BibTeX
@article{Reis2024,
author = {Reis, Gilmar and Augusto Dos Santos Moreira Silva, Eduardo and Carla Medeiros Silva, Daniela and Thabane, Lehana and Santiago Ferreira, Thiago and Vitor Quirino Dos Santos, Castilho and Paula Figueiredo Guimaraes Almeida, Ana and Cançado Monteiro Savassi, Leonardo and Dias de Figueiredo Neto, Adhemar and Lanna França Reis, Luiza and Helena de Souza Campos, Vitoria and Bitarães, Carina and Diniz Callegari, Eduardo and Izabel Campos Simplicio, Maria and Barra Ribeiro, Luciene and Oliveira, Rosemary and Harari, Ofir and Forrest, Jamie I and Lat, Prince Kumar and Dron, Louis and Thorlund, Kristian and Mills, Edward J},
title = {Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial},
journal = {The American Journal of Clinical Nutrition},
year = {2024},
doi = {10.1016/j.ajcnut.2024.06.016}
}
EUVIMED